Re: Design and endpoints of clinical trials in hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 100, Issue 21, 2008, Pages 1557-

  Di Maio, Massimo ^a   Daniele, Bruno ^b   Gallo, Ciro ^c   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b G RUMMO HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER FUNCTION; PRIORITY JOURNAL; BIOASSAY; LIVER TUMOR; METHODOLOGY; NOTE; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; CANCER SURVIVAL; LIVER FAILURE; PATIENT CARE; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; RESEARCH DESIGN;

EID: 55749084196     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn341     Document Type: Letter

References (7)

1. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10): 698-711.
2. Llovet J, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
3. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2008;26:4518.
4. Miller AA, Murry DJ, Owzar K, et al. Pharmacokinetic and phase I study of sorafenib for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction: CALGB 60301. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S):3538.
5. Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994;13(5-7):417-429.
6. Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials. 1999;20(4):343-352.
7. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23(28):7199-7206.